Medico Remedies Ltd
Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations[1]
- Market Cap ₹ 458 Cr.
- Current Price ₹ 55.2
- High / Low ₹ 79.8 / 34.8
- Stock P/E 45.4
- Book Value ₹ 7.53
- Dividend Yield 0.00 %
- ROCE 21.3 %
- ROE 17.6 %
- Face Value ₹ 2.00
Pros
- Company has delivered good profit growth of 44.0% CAGR over last 5 years
Cons
- Stock is trading at 7.37 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -3.04%
- The company has delivered a poor sales growth of 11.2% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
45 | 51 | 67 | 54 | 61 | 98 | 89 | 122 | 121 | 140 | 145 | 151 | |
43 | 48 | 63 | 50 | 58 | 95 | 86 | 117 | 114 | 131 | 132 | 136 | |
Operating Profit | 2 | 3 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 10 | 13 | 15 |
OPM % | 5% | 6% | 5% | 7% | 6% | 3% | 3% | 4% | 6% | 7% | 9% | 10% |
0 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 2 | 4 | 2 | 3 | |
Interest | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 |
Profit before tax | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 4 | 6 | 10 | 11 | 14 |
Tax % | 34% | 28% | 40% | 4% | 35% | 28% | 26% | 30% | 26% | 28% | 27% | 25% |
1 | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 5 | 7 | 8 | 10 | |
EPS in Rs | 0.25 | 0.25 | 0.35 | 0.25 | 0.15 | 0.19 | 0.20 | 0.31 | 0.58 | 0.87 | 1.00 | 1.22 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | 11% |
3 Years: | 8% |
TTM: | 4% |
Compounded Profit Growth | |
---|---|
10 Years: | 29% |
5 Years: | 44% |
3 Years: | 28% |
TTM: | 22% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 72% |
3 Years: | 41% |
1 Year: | 45% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 16% |
3 Years: | 18% |
Last Year: | 18% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1 | 2 | 2 | 3 | 4 | 4 | 4 | 4 | 17 | 17 | 17 | 17 |
Reserves | 7 | 12 | 13 | 13 | 23 | 24 | 26 | 28 | 20 | 27 | 36 | 46 |
8 | 8 | 14 | 19 | 13 | 14 | 14 | 15 | 13 | 10 | 8 | 15 | |
14 | 14 | 17 | 13 | 20 | 35 | 32 | 28 | 28 | 34 | 36 | 43 | |
Total Liabilities | 31 | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 77 | 87 | 96 | 120 |
8 | 8 | 7 | 7 | 7 | 12 | 13 | 15 | 18 | 22 | 21 | 21 | |
CWIP | 0 | 0 | 0 | 3 | 4 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 2 |
23 | 27 | 38 | 39 | 48 | 63 | 60 | 59 | 59 | 64 | 73 | 96 | |
Total Assets | 31 | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 77 | 87 | 96 | 120 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-3 | 5 | 5 | 1 | -11 | 6 | 8 | 3 | 5 | ||||
-3 | -5 | -4 | -3 | -17 | -2 | -7 | -3 | -3 | ||||
6 | -1 | -1 | 3 | 18 | -6 | -2 | -0 | -1 | ||||
Net Cash Flow | -0 | -0 | -0 | 0 | -10 | -2 | -0 | -1 | 1 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 49 | 53 | 107 | 122 | 102 | 109 | 98 | 82 | 92 | 94 | 125 | 138 |
Inventory Days | 81 | 76 | 63 | 96 | 125 | 74 | 99 | 58 | 76 | 69 | 54 | 90 |
Days Payable | 139 | 122 | 106 | 112 | 147 | 149 | 143 | 100 | 113 | 108 | 105 | 117 |
Cash Conversion Cycle | -10 | 6 | 64 | 105 | 80 | 33 | 54 | 39 | 54 | 54 | 75 | 111 |
Working Capital Days | 68 | 77 | 109 | 163 | 146 | 87 | 90 | 80 | 82 | 76 | 92 | 128 |
ROCE % | 11% | 10% | 11% | 10% | 9% | 8% | 8% | 10% | 15% | 21% | 21% | 21% |
Documents
Announcements
-
Intimation For Commencement Of Work For New Factory Under Regulation 30 (Read With Part B Of Schedule III) (LODR) Regulations, 2015 ("Listing Regulations')
15 May - Medico Remedies starts Rs.30 Cr new factory for antibiotics, adding 25 Cr revenue in 2 years.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 10 May
-
Appointment Of Secretarial Auditor & Approval Of Director''s Report Alongwith Annexures
8 May - Approved FY 2024-25 audited results; appointed new statutory and secretarial auditors for 5 years.
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
8 May - Audited FY25 results with profit growth; new statutory and secretarial auditors appointed subject to shareholder approval.
- Financial Results For March, 2025 8 May
Business Overview:[1][2]
MRL is a pharmaceutical formulation manufacturing and marketing company with focus on antibiotic, anti-infective, beta-lactam penicillin, cephalosporin, anti fungal, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins & supplements, hematinic and other drugs viz. NSAIDS, antihistaminic, anti-diabetics, cardiovascular drugs, antipyretic, analgesic, diuretics, anti-epileptics, antidepressants, antipsychotics, combination drug kits, dry syrups, ointments and cream & gel for various therapeutic segments